60
Participants
Start Date
July 25, 2007
Primary Completion Date
May 12, 2022
Study Completion Date
May 12, 2022
ABT-263
Tablet; Oral
Peter MacCallum Cancer Ctr /ID# 6583, Melbourne
The Royal Melbourne Hospital /ID# 5576, Parkville
North Shore University Hospital /ID# 12267, New Hyde Park
Universitaetsklinikum Koeln /ID# 5924, Cologne
University of Nebraska Medical Center /ID# 12261, Omaha
University of Texas MD Anderson Cancer Center /ID# 5575, Houston
Moores Cancer Center at UC San Diego /ID# 5566, La Jolla
Northwest Medical Specialties - Tacoma /ID# 26428, Tacoma
Dana-Farber Cancer Institute /ID# 5547, Boston
Leicester Royal Infirmary /ID# 15081, Leicester
Lead Sponsor
Collaborators (1)
Genentech, Inc.
INDUSTRY
AbbVie
INDUSTRY